Loss of imprinting in disease progression in chronic myelogenous leukemia

Gurvaneet S. Randhawa, Hengmi Cui, Janet A. Barletta, Liora Z. Strichman-Almashanu, Moshe Talpaz, Hagop Kantarjian, Albert B. Deisseroth, Richard C. Champlin, Andrew P Feinberg

Research output: Contribution to journalArticle

Abstract

The pathophysiologic role of the Philadelphia chromosome translocation in chronic myelogenous leukemia (CML) has been known for nearly 20 years. However, the most significant morbidity and mortality in CML are caused by progression to blast crisis, about which comparatively little is known at the molecular level. Genomic imprinting is a chromosomal modification leading to parental-origin-specific gene expression in somatic cells. Recently, we and others have described loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to biallelic rather than monoallelic expression in a wide variety of solid tumors. We have now examined the imprinting status of IGF2 in samples from CML patients in stable phase, accelerated phase, and blast crisis. Five of six stable-phase patients showed normal imprinting, but LOI was found in all six cases of advanced disease (three accelerated phase, three blast crisis), which was statistically highly significant (P <.01). Thus, LOI represents a novel type of genetic alteration in CML that appears to be specifically associated with disease progression.

Original languageEnglish (US)
Pages (from-to)3144-3147
Number of pages4
JournalBlood
Volume91
Issue number9
StatePublished - May 1 1998

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blast Crisis
Disease Progression
Insulin-Like Growth Factor II
Chromosomes
Genomic Imprinting
Gene expression
Philadelphia Chromosome
Tumors
Genes
Morbidity
Gene Expression
Mortality
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Randhawa, G. S., Cui, H., Barletta, J. A., Strichman-Almashanu, L. Z., Talpaz, M., Kantarjian, H., ... Feinberg, A. P. (1998). Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood, 91(9), 3144-3147.

Loss of imprinting in disease progression in chronic myelogenous leukemia. / Randhawa, Gurvaneet S.; Cui, Hengmi; Barletta, Janet A.; Strichman-Almashanu, Liora Z.; Talpaz, Moshe; Kantarjian, Hagop; Deisseroth, Albert B.; Champlin, Richard C.; Feinberg, Andrew P.

In: Blood, Vol. 91, No. 9, 01.05.1998, p. 3144-3147.

Research output: Contribution to journalArticle

Randhawa, GS, Cui, H, Barletta, JA, Strichman-Almashanu, LZ, Talpaz, M, Kantarjian, H, Deisseroth, AB, Champlin, RC & Feinberg, AP 1998, 'Loss of imprinting in disease progression in chronic myelogenous leukemia', Blood, vol. 91, no. 9, pp. 3144-3147.
Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998 May 1;91(9):3144-3147.
Randhawa, Gurvaneet S. ; Cui, Hengmi ; Barletta, Janet A. ; Strichman-Almashanu, Liora Z. ; Talpaz, Moshe ; Kantarjian, Hagop ; Deisseroth, Albert B. ; Champlin, Richard C. ; Feinberg, Andrew P. / Loss of imprinting in disease progression in chronic myelogenous leukemia. In: Blood. 1998 ; Vol. 91, No. 9. pp. 3144-3147.
@article{994c0d3e8a53484298f2fc71f2ffb222,
title = "Loss of imprinting in disease progression in chronic myelogenous leukemia",
abstract = "The pathophysiologic role of the Philadelphia chromosome translocation in chronic myelogenous leukemia (CML) has been known for nearly 20 years. However, the most significant morbidity and mortality in CML are caused by progression to blast crisis, about which comparatively little is known at the molecular level. Genomic imprinting is a chromosomal modification leading to parental-origin-specific gene expression in somatic cells. Recently, we and others have described loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to biallelic rather than monoallelic expression in a wide variety of solid tumors. We have now examined the imprinting status of IGF2 in samples from CML patients in stable phase, accelerated phase, and blast crisis. Five of six stable-phase patients showed normal imprinting, but LOI was found in all six cases of advanced disease (three accelerated phase, three blast crisis), which was statistically highly significant (P <.01). Thus, LOI represents a novel type of genetic alteration in CML that appears to be specifically associated with disease progression.",
author = "Randhawa, {Gurvaneet S.} and Hengmi Cui and Barletta, {Janet A.} and Strichman-Almashanu, {Liora Z.} and Moshe Talpaz and Hagop Kantarjian and Deisseroth, {Albert B.} and Champlin, {Richard C.} and Feinberg, {Andrew P}",
year = "1998",
month = "5",
day = "1",
language = "English (US)",
volume = "91",
pages = "3144--3147",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Loss of imprinting in disease progression in chronic myelogenous leukemia

AU - Randhawa, Gurvaneet S.

AU - Cui, Hengmi

AU - Barletta, Janet A.

AU - Strichman-Almashanu, Liora Z.

AU - Talpaz, Moshe

AU - Kantarjian, Hagop

AU - Deisseroth, Albert B.

AU - Champlin, Richard C.

AU - Feinberg, Andrew P

PY - 1998/5/1

Y1 - 1998/5/1

N2 - The pathophysiologic role of the Philadelphia chromosome translocation in chronic myelogenous leukemia (CML) has been known for nearly 20 years. However, the most significant morbidity and mortality in CML are caused by progression to blast crisis, about which comparatively little is known at the molecular level. Genomic imprinting is a chromosomal modification leading to parental-origin-specific gene expression in somatic cells. Recently, we and others have described loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to biallelic rather than monoallelic expression in a wide variety of solid tumors. We have now examined the imprinting status of IGF2 in samples from CML patients in stable phase, accelerated phase, and blast crisis. Five of six stable-phase patients showed normal imprinting, but LOI was found in all six cases of advanced disease (three accelerated phase, three blast crisis), which was statistically highly significant (P <.01). Thus, LOI represents a novel type of genetic alteration in CML that appears to be specifically associated with disease progression.

AB - The pathophysiologic role of the Philadelphia chromosome translocation in chronic myelogenous leukemia (CML) has been known for nearly 20 years. However, the most significant morbidity and mortality in CML are caused by progression to blast crisis, about which comparatively little is known at the molecular level. Genomic imprinting is a chromosomal modification leading to parental-origin-specific gene expression in somatic cells. Recently, we and others have described loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to biallelic rather than monoallelic expression in a wide variety of solid tumors. We have now examined the imprinting status of IGF2 in samples from CML patients in stable phase, accelerated phase, and blast crisis. Five of six stable-phase patients showed normal imprinting, but LOI was found in all six cases of advanced disease (three accelerated phase, three blast crisis), which was statistically highly significant (P <.01). Thus, LOI represents a novel type of genetic alteration in CML that appears to be specifically associated with disease progression.

UR - http://www.scopus.com/inward/record.url?scp=0032080161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032080161&partnerID=8YFLogxK

M3 - Article

C2 - 9558368

AN - SCOPUS:0032080161

VL - 91

SP - 3144

EP - 3147

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -